<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02480101</url>
  </required_header>
  <id_info>
    <org_study_id>LAIV-H7N9-01</org_study_id>
    <nct_id>NCT02480101</nct_id>
  </id_info>
  <brief_title>Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine</brief_title>
  <official_title>Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Anhui/2013/61 (H7N9) Influenza Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Institute of Influenza, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Experimental Medicine, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Research Institute of Influenza, Russia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single centre phase I, double-blind placebo-controlled study to assess&#xD;
      reactogenicity, safety and immunogenicity of a live monovalent A/17/Anhui/2013/61 (H7N9)&#xD;
      influenza vaccine in healthy male and female adults, 18 through 49 years of age .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immediate reactions</measure>
    <time_frame>2 hours</time_frame>
    <description>Immediate reactions occurring within two hours of administration of any dose, measured as observed by study staff or reported by the subject to study staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited adverse events</measure>
    <time_frame>Greater than two hours after administration of any dose of study vaccine or placebo through 6 days following any dose</time_frame>
    <description>Adverse events commonly associated with intranasal vaccination (solicited local and systemic reactions), measured as observed by study staff or reported by the subject to study staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in laboratory findings</measure>
    <time_frame>Days 3, 6 and 34</time_frame>
    <description>Abnormal laboratory findings from blood and urine specimens</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (SAEs)</measure>
    <time_frame>4 weeks of receipt of any dose</time_frame>
    <description>All SAEs during 56 days, as observed by study staff, reported by the subject to study staff, or noted by the subject on a diary card, including abnormal laboratory findings from blood specimens collected on Days 28 (pre-vaccination) and 56</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune responses</measure>
    <time_frame>Days 0, 28 and 56</time_frame>
    <description>Immune responses was parameterized as the proportion of subjects with at least a four-fold rise after each dose from baseline or as the mean titer after each dose in any of the following:&#xD;
Serum hemagglutination inhibition (HAI) antibodies&#xD;
Serum neutralizing antibodies&#xD;
Serum immunoglobulin class A (IgA) or immunoglobulin class G (IgG) antibodies measured by enzyme-linked immunosorbent assay (ELISA)&#xD;
Secretory IgA antibodies from the nasal mucosa detected in nasal wick specimens using ELISA&#xD;
Secretory IgA antibodies in saliva specimens using ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virus shedding</measure>
    <time_frame>Days 0-6 after each dose</time_frame>
    <description>Virus shedding with virus detected by real-time reverse transcriptase polymerase chain reaction rRTPCR in nasal swabs at any time point (at day of vaccination and daily during hospitalization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virus stability</measure>
    <time_frame>Days 0-6 after each dose</time_frame>
    <description>Virus stability (virus detected and sequenced after inoculation into chicken eggs)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cellular immune responses (cytokine and T-cell)</measure>
    <time_frame>Days 0, 28 and 56</time_frame>
    <description>Cellular immune responses (cytokine and T-cell) was measured using isolated peripheral blood mononuclear cells (PBMCs) tested by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT) assay.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>H7N9 LAIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>H7N9 live influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lyophilized purified allantoic fluid of chicken embryos with stabilizers</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H7N9 live influenza vaccine</intervention_name>
    <description>H7N9 live influenza vaccine</description>
    <arm_group_label>H7N9 LAIV</arm_group_label>
    <other_name>LAIV H7N9</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lyophilized purified allantoic fluid of chicken embryos with stabilizers</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Legal male or female adult 18 through 49 years of age at the enrollment visit.&#xD;
&#xD;
          -  Literate and willing to provide written informed consent.&#xD;
&#xD;
          -  A signed informed consent.&#xD;
&#xD;
          -  Free of obvious health problems, as established by the medical history and screening&#xD;
             evaluations, including physical examination.&#xD;
&#xD;
          -  Capable and willing to complete diary cards and willing to return for all follow-up&#xD;
             visits&#xD;
&#xD;
          -  Willing to comply with the rules of the isolation unit (including willing and able to&#xD;
             take oseltamivir influenza antiviral medication, should that be recommended by a study&#xD;
             physician).&#xD;
&#xD;
          -  For females, willing to take reliable birth control measures through day 56.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical trial involving any therapy within the previous&#xD;
             three months or planned enrollment in such a trial during the period of this study.&#xD;
&#xD;
          -  Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to&#xD;
             postpone receipt of such vaccines until four weeks after study completion.&#xD;
&#xD;
          -  Practice of nasal irrigation on a regular basis within the past six months or has&#xD;
             engaged in nasal irrigation within two weeks prior to enrollment.&#xD;
&#xD;
          -  Recent history of frequent nose bleeds (more than 5 within the past year).&#xD;
&#xD;
          -  Clinically relevant abnormal paranasal anatomy.&#xD;
&#xD;
          -  Recent history (within the past month) of rhino or sinus surgery, or surgery for any&#xD;
             traumatic injury of the nose.&#xD;
&#xD;
          -  Current or recent (within two weeks of enrollment) acute respiratory illness with or&#xD;
             without fever.&#xD;
&#xD;
          -  Other acute illness at the time of study enrollment.&#xD;
&#xD;
          -  Receipt of immune globulin or other blood products within three months prior to study&#xD;
             enrollment or planned receipt of such products during the period of subject&#xD;
             participation in the study.&#xD;
&#xD;
          -  Chronic administration (defined as more than 14 consecutively-prescribed days) of&#xD;
             immunosuppressants or other immune-modulating therapy within six months prior to study&#xD;
             enrollment (for corticosteroids, this means prednisone or equivalent, 0.5 mg per kg&#xD;
             per day; topical steroids are allowed, exclusive of nasal.)&#xD;
&#xD;
          -  Participation in any previous trial of any H7 or H5 containing influenza vaccine.&#xD;
&#xD;
          -  History of bronchial asthma.&#xD;
&#xD;
          -  Hypersensitivity and allergy reactions after previous administration of any vaccine.&#xD;
&#xD;
          -  History of wheezing after past receipt of any live influenza vaccine.&#xD;
&#xD;
          -  Other AE following immunization (body temperature more than 40Â°C, collapse,&#xD;
             non-febrile seizures, anaphylaxis), at least possibly related to previous receipt of&#xD;
             any vaccine (not only influenza).&#xD;
&#xD;
          -  Suspected or known hypersensitivity to any of the study vaccine components, including&#xD;
             chicken or egg protein.&#xD;
&#xD;
          -  Seasonal (autumnal) hypersensitivity to the natural environment.&#xD;
&#xD;
          -  Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, metabolic,&#xD;
             neurologic, psychiatric or renal functional abnormality, as determined by medical&#xD;
             history, physical examination or clinical laboratory screening tests, which in the&#xD;
             opinion of the investigator, might interfere with the study objectives. Subjects with&#xD;
             physical examination findings or clinical laboratory screening results which would be&#xD;
             graded 2 or higher on the AE severity grading scale will be excluded from entry into&#xD;
             the study and will be excluded from receipt of dose two of study vaccine or placebo.&#xD;
&#xD;
          -  History of leukemia or any other blood or solid organ cancer.&#xD;
&#xD;
          -  History of thrombocytopenic purpura or known bleeding disorder.&#xD;
&#xD;
          -  History of seizures.&#xD;
&#xD;
          -  Known or suspected immunosuppressive or immunodeficient condition of any kind,&#xD;
             including HIV infection.&#xD;
&#xD;
          -  Known chronic HBV or HCV infection.&#xD;
&#xD;
          -  Known tuberculosis infection or evidence of previous tuberculosis exposure.&#xD;
&#xD;
          -  History of chronic alcohol abuse and/or illegal drug use.&#xD;
&#xD;
          -  Claustrophobia or sociophobia.&#xD;
&#xD;
          -  Pregnancy or lactation (a negative pregnancy test will be required before&#xD;
             administration of study vaccine or placebo for all women of childbearing potential).&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would increase the health risk&#xD;
             to the subject if he/she participates in the study or would interfere with the&#xD;
             evaluation of the study objectives.&#xD;
&#xD;
          -  Allergic, including anaphylactic, reactions to the introduction of any vaccines in the&#xD;
             subject's medical history (not only flu vaccine).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larisa G Rudenko, MD PhD DSc</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Experimental Medicine</affiliation>
  </overall_official>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 16, 2015</study_first_submitted>
  <study_first_submitted_qc>June 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2015</study_first_posted>
  <last_update_submitted>June 19, 2015</last_update_submitted>
  <last_update_submitted_qc>June 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Research Institute of Influenza, Russia</investigator_affiliation>
    <investigator_full_name>Oleg Kiselev</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>influenza vaccine pandemic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

